{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:25:54Z","timestamp":1788297954115,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005933","name":"Camurus Lipid Research Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100005933","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pilgrim Trust","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12954-019-0296-4","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T04:03:42Z","timestamp":1554264222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Prolonged-release opioid agonist therapy: qualitative study exploring patients\u2019 views of 1-week, 1-month, and 6-month buprenorphine formulations"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1502-5983","authenticated-orcid":false,"given":"Joanne","family":"Neale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte N. E.","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Strang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"296_CR1","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1517\/14656560903037168","volume":"10","author":"AL Stotts","year":"2009","unstructured":"Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009;10:1727\u201340.","journal-title":"Expert Opin Pharmacother"},{"key":"296_CR2","unstructured":"SAMHSA (Substance Abuse and Mental Health Services Administration). Medications to treat opioid use disorder. Treatment improvement protocol (TIP) series 63, full document. HHS publication no. (SMA) 18-5063FULLDOC. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018."},{"key":"296_CR3","unstructured":"European Medicines Agency. Buvidal\u00ae. \n                    https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/buvidal\n                    \n                   (2018). Accessed 23 Dec 2018."},{"issue":"Suppl 2","key":"296_CR4","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","volume":"70","author":"SL Walsh","year":"2003","unstructured":"Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70(Suppl 2):S13\u201327.","journal-title":"Drug Alcohol Depend"},{"key":"296_CR5","volume-title":"Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04\u20133939","author":"Center for Substance Abuse Treatment","year":"2004","unstructured":"Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04\u20133939. Rockville: Substance Abuse and Mental Health Services Administration; 2004."},{"key":"296_CR6","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.2147\/DDDT.S109331","volume":"11","author":"M Itzoe","year":"2017","unstructured":"Itzoe M, Guarnieri M. New developments in managing opioid addiction: impact of a subdermal buprenorphine implant. Drug Des Devel Ther. 2017;11:1429\u201337.","journal-title":"Drug Des Devel Ther"},{"key":"296_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1360-0443.2006.01348.x","volume":"101","author":"S Sigmon","year":"2006","unstructured":"Sigmon S, Moody DE, Nuwayser ES, Bigelow GE. An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction. 2006;101:420\u201332.","journal-title":"Addiction."},{"key":"296_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/add.13539","volume":"112","author":"SC Sigmon","year":"2016","unstructured":"Sigmon SC, Bigelow GE. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential. Addiction. 2016;112:386\u20137.","journal-title":"Addiction."},{"key":"296_CR9","volume-title":"Drug misuse and dependence: UK guidelines on clinical management","author":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group","year":"2017","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health; 2017."},{"key":"296_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-200220003-00001","volume":"20","author":"JA DiMasi","year":"2002","unstructured":"DiMasi JA. The value of improving the productivity of the drug development process. Faster times and better decisions. PharmacoEconomics. 2002;20:1\u201310.","journal-title":"PharmacoEconomics."},{"key":"296_CR11","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1111\/add.12315","volume":"108","author":"RN Rosenthal","year":"2013","unstructured":"Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, Patkwar A, Chavoustie S, Blasey C, Sigmon S, Beebe KL. Buprenophine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine\/naloxone. Addiction. 2013;108:2141\u20139.","journal-title":"Addiction."},{"key":"296_CR12","first-page":"2017","volume-title":"Drug safety evaluation","author":"SC Gad","year":"2017","unstructured":"Gad SC. Drug safety evaluation. Hoboken: Wiley; 2017. p. 2017."},{"key":"296_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","volume":"178","author":"MR Lofwall","year":"2018","unstructured":"Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, Oosman S, Peterson S, Chen M, Kim S. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178:764\u201373.","journal-title":"JAMA Intern Med"},{"key":"296_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.03.057","volume":"189","author":"J Neale","year":"2018","unstructured":"Neale J, Tompkins CNE, McDonald R, Strang J. Implants and depot injections for treating opioid dependence: qualitative study of people who use or have used heroin. Drug Alcohol Depend. 2018;189:1\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"296_CR15","unstructured":"Neale J, Tompkins CNE, McDonald R, Strang J. Patient views of opioid pharmacotherapy bio-delivery systems: qualitative study to assist treatment decision making. Experimental and Clinical Psychopharmacology. In press; \n                    http:\/\/psycnet.apa.org\/doi\/10.1037\/pha0000217\n                    \n                  ."},{"key":"296_CR16","volume-title":"MAXQDA computer programme","author":"VERBI Software","year":"2016","unstructured":"VERBI Software. MAXQDA computer programme. Berlin: VERBI; 2016."},{"key":"296_CR17","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/add.13314","volume":"111","author":"J Neale","year":"2016","unstructured":"Neale J. Iterative categorisation (IC): a systematic technique for analyzing qualitative data. Addiction. 2016;111:1096\u2013106.","journal-title":"Addiction."},{"key":"296_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13722-015-0034-5","volume":"10","author":"K Ahamad","year":"2015","unstructured":"Ahamad K, Milloy MJ, Nguyen P, Uhlmann S, Johnson C, Korthuis TP, Kerr T, Wood E. Factors associated with willingness to take extended-release naltrexone among injection drug users. Addict Sci Clin Pract. 2015;10:12.","journal-title":"Addict Sci Clin Pract"},{"key":"296_CR19","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.2147\/PPA.S180641","volume":"12","author":"M Gilman","year":"2018","unstructured":"Gilman M, Li L, Hudson K, Lumley T, Myers G, Corte C, Littlewood R. Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine. Patient Prefer Adherence. 2018;12:2123\u20139.","journal-title":"Patient Prefer Adherence"},{"key":"296_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/10503300802702113","volume":"19","author":"E Nutt Williams","year":"2009","unstructured":"Nutt Williams E, Morrow SL. Achieving trustworthiness in qualitative research: a pan-paradigmatic perspective. Psychother Res. 2009;19:576\u201382.","journal-title":"Psychother Res"},{"key":"296_CR21","volume-title":"What recovery outcomes does the evidence tell us we can expect? Second report of the recovery committee","author":"Advisory Council on the Misuse of Drugs","year":"2013","unstructured":"Advisory Council on the Misuse of Drugs. What recovery outcomes does the evidence tell us we can expect? Second report of the recovery committee. London: Advisory Council on the Misuse of Drugs; 2013."},{"key":"296_CR22","volume-title":"Drug strategy 2010: reducing demand, restricting supply, building recovery: supporting people to live drug free life","author":"HM Government","year":"2010","unstructured":"HM Government. Drug strategy 2010: reducing demand, restricting supply, building recovery: supporting people to live drug free life. London: HM Government; 2010."},{"key":"296_CR23","volume-title":"2017 Drug Strategy","author":"HM Government","year":"2017","unstructured":"HM Government. 2017 Drug Strategy. London: HM Government; 2017."},{"key":"296_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1146\/annurev.publhealth.18.1.379","volume":"18","author":"GF Brown","year":"1997","unstructured":"Brown GF, Moskowitz EH. Moral and policy issues in long-acting contraception. Annu Rev Public Health. 1997;18:379\u2013400.","journal-title":"Annu Rev Public Health"},{"key":"296_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1136\/medethics-2018-104855","volume":"44","author":"RT Behmer Hansen","year":"2018","unstructured":"Behmer Hansen RT, Arora KS. Consenting to invasive contraceptives: an ethical analysis of adolescent decision-making authority for long-acting reversible contraception. J Med Ethics. 2018;44:585\u20138.","journal-title":"J Med Ethics"},{"key":"296_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.comppsych.2004.02.003","volume":"45","author":"LW Roberts","year":"2004","unstructured":"Roberts LW, Geppert CM. Ethical use of long-acting medications in the treatment of severe and persistent mental illness. Compr Psychiatry. 2004;45:161\u20137.","journal-title":"Compr Psychiatry"},{"key":"296_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/inm.12105","volume":"24","author":"JP Smith","year":"2015","unstructured":"Smith JP, Herber OR. Ethical issues experienced by mental health nurses in the administration of antipsychotic depot and long-acting intramuscular injections: a qualitative study. Int J Ment Health Nurs. 2015;24:222\u201330.","journal-title":"Int J Ment Health Nurs"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0296-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-019-0296-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0296-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T19:21:34Z","timestamp":1585768894000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-019-0296-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["296"],"URL":"https:\/\/doi.org\/10.1186\/s12954-019-0296-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]},"assertion":[{"value":"1 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received approval from the Psychiatry, Nursing and Midwifery Research Ethics Subcommitttee (PNM RESC), King\u2019s College London (HR-17\/18-5957).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Joanne Neale has received honoraria and research grants from pharmaceutical companies: Camurus AB and Mundipharma International Ltd. John Strang is a researcher and clinician who has worked with a range of types of treatment and rehabilitation service-providers. He has also worked with a range of governmental and non-governmental organizations, and with pharmaceutical companies to seek to identify new or improved treatments from whom he and his employer (King\u2019s College London) have received honoraria, travel costs, and\/or consultancy payments. This has included discussions with Camurus AB, Indivior and Molteni Farma (all three of whom have developed ultra-long-acting buprenorphine formulations) and also an oversight role for the UK part of a safety trial of CAM2038\/Buvidal\u00ae, the product discussed in this paper. For a fuller account, see John Strang\u2019s web-page at:\n                      \n                      . Charlotte Tompkins received salary support from Camurus AB whilst undertaking this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"25"}}